Compare Becton Dickinson and Co (BDX) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Liberty Global Ltd Class C — how do they compare? Becton Dickinson and Co trades at $156.5 (market cap $41.51B), while Liberty Global Ltd Class C trades at $10.47 (market cap $3.59B). The key difference: Becton Dickinson and Co is far larger — about 11.6× Liberty Global Ltd Class C's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| BDX | LBTYK | |
|---|---|---|
Market Cap | $41.51B | $3.59B |
Sector | Health | Technology |
52-Week High | $185.39 | $12.67 |
52-Week Low | $135.49 | $10.07 |
Enterprise Value | $57.97B | $10.88B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
LBTYK trades at $10.54, up 2.63% today, but technical indicators are bearish with a negative net income margin of -109.66% for 2026. The stock shows a low P/S of 0.71 and P/B of 0.37, indicating potential undervaluation. Recent news highlights the planned 2027 spin-off and Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly positive with 69% buy ratings, though earnings have been volatile with a significant miss in Q4 2025.
The outlook is mixed: the spin-off offers upside potential, but persistent losses and high debt pose risks. Investors should weigh the sum-of-the-parts valuation opportunity against operational challenges and market volatility. The stock remains speculative with a bearish technical trend despite positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
